Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist developed by Structure Therapeutics.[1] It is delivered orally and is in a Phase II trial as of 2023.[2][3][4] In June 2024, Structure Therapeutics reported positive topline data from a Phase 2a obesity study in which GSBR-1290 demonstrated clinically meaningful and statistically significant placebo-adjusted mean weight loss and generally favorable safety and tolerability results.[5]
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
Chemical and physical data | |
Formula | C49H55FN9O6P |
Molar mass | 916.008 g·mol−1 |
|
References
edit- ^ Mao, Ting; Meng, Qinghua; Zhang, Haizhen; Zhang, Jinqiang J.; Shi, Songting; Guan, Zhibo; Jiang, Xinglong; Zhang, Fang; Lei, Hui; Lin, Xichen (20 June 2023). "760-P: Discovery of GSBR-1290, a Highly Potent, Orally Available, Novel Small Molecule GLP-1 Receptor Agonist". Diabetes. 72 (Supplement_1). doi:10.2337/db23-760-P. S2CID 259430363.
- ^ "Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity". BioSpace. 25 May 2023. Retrieved 4 November 2023.
- ^ "Structure announces positive results from oral GLP-1 receptor agonist gsbr-1290". Bariatric News. 2 October 2023. Retrieved 4 November 2023.
- ^ Satija, Bhanvi (29 September 2023). "Structure Therapeutics surges as early data from obesity pill tops expectations". Reuters. Retrieved 4 November 2023.
- ^ "Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290". BioSpace. 2024-06-03. Retrieved 2024-10-24.